RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2031

Overview

Close to 10 million fatalities reported in 2020 were observed to be associated with cancer, which is believed to be one of the leading causes of death, globally. One of the primary reasons for the high mortality rate associated with this condition is anticipated to be late diagnosis, which eventually results in delayed treatment, further leading to severe compromises with chances of survival of a patient. Moreover, post the onset of the COVID-19 pandemic, the treatment of cancer patients has become arduous, as patient visits are being cancelled by healthcare facilities in order to preserve resources and prevent patients from getting infected with SARS-CoV-2. Further, as per the National Cancer Institute, the delay in screening and treatment of cancer patients due to the COVID-19 pandemic is likely to result in 10,000 deaths, which could have been otherwise prevented, over the next decade. Specifically, in 2020, the global prevalence of human cancers was estimated to be 50.5 million; of this, majority of the cases were reported to be of breast cancer and lung cancer. Since a large share of the population remains affected with various oncological indications, cancer therapeutics continue to be one of the most active segments, in terms of drug development efforts, within the pharmaceutical industry. 

Given the complexities associated with conventional cancer treatment options, such as chemotherapy and radiation therapy, drug developers engaged in this domain have shifted their focus on the development of drugs against specific oncogenic mutations that are primarily responsible for the disease development and/or progression. It is worth mentioning that one such target (RAS), which was previously considered undruggable, was found to be associated with 30% of cancers in humans. Over the years, several drug candidates have been evaluated to target specific RAS mutated genes. In 2021, LUMAKRAS™ (sotorasib), a RAS targeting small molecule was approved by the USFDA for the treatment of metastatic non-small cell lung cancer in patients with KRAS G12C mutations. Given its high efficacy and good safety profile, significant efforts are being made to evaluate the potential of the aforementioned drug across multiple solid tumor indications, such as colorectal cancer. Presently, several companies (including big pharma players), independently or in collaboration with other stakeholders, are actively engaged in the development of RAS targeting therapies. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.

The ‘RAS Targeting Therapies by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031, report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of this industry, over the next decade. Further, the study underlines an in-depth analysis of players engaged in the development of RAS targeting therapies. 

Amongst other elements, the report features:

• A detailed overview of the current market landscape of RAS targeting therapies, along with information on several relevant parameters, such as current status of development (marketed, clinical, pre-clinical and discovery), phase of development (phase III, phase II, phase I/II and phase I), type of molecule (biologic and small molecule), type of therapy (monotherapy and combination therapy), target therapeutic area (blood cancer, colorectal cancer, esophageal cancer, head and neck cancer, lung cancer, pancreatic cancer, skin cancer, and undisclosed solid tumors), target gene (HRAS, KRAS and NRAS), line of treatment and route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral and subcutaneous), In addition, it presents details of companies engaged in the development of RAS targeting therapies, based on several relevant parameters, such as year of establishment, employee count, and geographical presence.
• An in-depth analysis of completed, ongoing and planned clinical trials of various RAS targeting therapies, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors/collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and regional distribution of trials.
• An insightful competitive analysis, highlighting the key players engaged in the domain (on the basis of the strength of their respective development portfolios), along with information on several relevant parameters, such as company size and stage of development of lead molecules. 
• Elaborate profiles of the key players engaged in offering RAS targeting therapies. Each profile features a brief overview of the company, details on its product portfolio, recent developments and an informed future outlook. 
• A detailed review of close to 1,600 peer-reviewed, scientific articles related to research on RAS targeting therapies, which have been published between January 2020 and April 2021. It also discusses the trends across year of publication, focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in this domain and impact factor of the journal).
• An analysis of the recent partnerships inked between various players engaged in the development of RAS targeting therapies, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as R&D agreements, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in this domain, during the period 2016-2021. 
• A detailed analysis of various investments, such as venture capital financing, debt financing, grants/awards, capital raised from IPOs and subsequent offerings that were undertaken by engaged in this domain, during the period 2016-2021. 
• An elaborate discussion on the various commercialization strategies that have been adopted by drug developers engaged in this domain across different stages of therapy development, including prior to drug launch, at/during drug launch and post-marketing stage.

One of the key objectives of the report was to estimate the existing market size and future growth potential associated with RAS targeting therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption rates and likely annual treatment cost of RAS targeting therapies, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target indication (acute myeloid leukemia, colorectal cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, Phelan-Mcdermid syndrome and skin cancer), [B] type of molecule (biologic and small molecule), [C] type of therapy (monotherapy, combination therapy), [D] route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral, and subcutaneous), and [E] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for the future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

• Which are the key candidates being developed at preclinical and clinical stages of development?
• What are the key therapeutic indications for which RAS targeting therapies are being investigated?
• What are the key challenges faced by stakeholders engaged in this domain?
• Who are the leading industry and non-industry players engaged in the development of RAS targeting therapies?
• What are the key geographies where research focused on RAS mutated cancer is being conducted?
• Who are the key investors in this domain? 
• What kind of partnership models are commonly adopted by industry stakeholders? 
• What are the key value drivers that are likely to influence the evolution of this upcoming market?
• How is the current and future market opportunity likely to be distributed across key market segments?